(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

SULINNO

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

SULINNO

ST13

US500000079304552

Class

5

Filing

79304552

Registration

6541740

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

30

Latest update

05/16/2022

Trademark type

Combined

Nice classes

5

Filing date

09/23/2020

Registration date

11/02/2021

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

11/02/2021

Last transaction

11/02/2021

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

5

Owner type

99

Owner location

CN

Examiner

LE, MARGARET

Law office

M90

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Innovent Biologics (Suzhou) Co., Ltd.

Representatives

Paulo A. de Almeida Patel & Almeida, P.C.

Technical classification

Nice Classes

Class 5

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Medicines for the treatment of cancer for human purposes; biochemical medicines for the treatment of cancer; liquid medicines for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; blood productsblood plasmablood for medical purposes; chemical reagents for medical or veterinary purposes; biological preparations for the treatment of cancer for medical purposes; biological tissue cultures for veterinary purposes; drugs for the treatment of cancer for medical purposes; diagnostic preparations for medical purposes; vaccines; injectable solutions for the treatment of anaphylactic reactions

Publications

History of USPTO decisions and trademark events.

30 publications found

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

05/16/2022

FICS

FINAL DISPOSITION NOTICE SENT TO IB

04/25/2022

FIMP

FINAL DISPOSITION PROCESSED

04/25/2022

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

02/02/2022

R.PR

REGISTERED-PRINCIPAL REGISTER

11/02/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

08/17/2021

PUBO

PUBLISHED FOR OPPOSITION

08/17/2021

GPNX

NOTIFICATION PROCESSED BY IB

08/15/2021

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

07/28/2021

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

07/28/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

07/28/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

07/12/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

06/30/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

06/29/2021

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

06/29/2021

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

04/08/2021

GNFR

FINAL REFUSAL E-MAILED

04/08/2021

CNFR

FINAL REFUSAL WRITTEN

04/08/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

04/02/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

04/01/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

04/01/2021

RFNT

REFUSAL PROCESSED BY IB

03/22/2021

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

03/03/2021

RFRR

REFUSAL PROCESSED BY MPU

03/02/2021

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

02/26/2021

CNRT

NON-FINAL ACTION WRITTEN

02/25/2021

MAFR

APPLICATION FILING RECEIPT MAILED

02/23/2021

DOCK

ASSIGNED TO EXAMINER

02/19/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

02/19/2021

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

02/18/2021

Continuous trademark protection

Get notified about every new filing that threatens SULINNO or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.